reasons why alan will deliver next week, page-9

regarding point 3.

Understand the excitement and sentiment at the moment. Its very encouraging....but re stability trials. Sentiment dorsnt match releases of the company at the moment.

For instance, we have the announced and understood generic drug which should be rolling out commercially as we speak according to UNS/AS.

Next we have Sanofi, who started trials and STs back in 2011. Another announcement the week after Sanofi received initial batches in 2011 spoke of a company doing stability trials.

Then skip forward to Dec 2012 where we received an announcement of another company commencing stability trials.

These announcement generally can be correlated to spikes in revenue...and looking at when revenue flat lines that coincides with nothing in the way of announcements.

So that is Sanofi plus 3 companies doing stability trials (one of which is already a 10MM a year supply agreement) Does that match peoples expectations of how many people are out there trialling Unifill????

If they all sign up this year it will likely be 80-120million a year revenue which is covering operating costs. Are all likely to sign up, remembering some drugs are still in trial phase???